System Alert

Reminder: 45 CFR Part 75, Subpart F requires recipients expending $750,000 or more in Federal awards during their FYs to complete Single Audits and submit the related reports to the Federal Audit Clearinghouse (FAC) within 9 months after the end of their audit periods. Please email SARFollowUp@hrsa.gov with questions.

 

System Alert

HRSA has been informed that multiple phishing emails were sent to HRSA grantees. The impersonating phishing emails include a link to a fake site instructing grantees to enter Personally Identifiable Information (PII), including SSN, Driver’s License, and Tax information. HRSA will never send you an email asking you to click a link and confirm your email address or other user personal information.

Please remain vigilant when you receive emails to ensure that they are from a legitimate HRSA user and not an email impersonating a HRSA email address. You can hover over the email address to confirm its origin.

If you have submitted such information, please contact your internal IT security team for assistance. Also, if you have provided any personally identifiable information (PII), please visit https://www.ic3.gov/ to file a complaint. IC3 website is managed by a law enforcement agency.

If you have submitted such information, please also inform your HRSA Grant Project Officer and/or EHBs Customer Support Center using the Contact Form or calling 877-464-4772 that your PII may have been exposed.

Skip to Main Content

HRSA Electronic Handbooks

Funding Cycle View

Expand

Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV

  • Program Name:Special Projects of National Significance - Minority HIV/AIDS Fund
  • Activity Code:U1S
  • Application Available:4/21/2022
  • Application Deadline:6/21/2022
  • Created By:Beach, Dawn
  • Created On:2/7/2022
  • Last Updated by:Wildberger, William
  • Last Updated On:4/21/2022
  • Estimated Project Start Date:9/1/2022
 
Collapse

 Details of the changes posted in this announcement

Not Available
 
Collapse

 Announcement Information

Announcement Number HRSA-22-155
Announcement Code
CFDA Number 93.899
Provisional No
Activity Code U1S
Competitive Yes
Fiscal Year 2022
 
Collapse

 Purpose

This notice announces the opportunity to apply for funding under the Increasing Uptake of Long-Acting Injectable Antiretrovirals Among People with HIV cooperative agreement Increasing viral suppression and client retention in care are critical components of meeting the goals of the National HIV/AIDS Strategy (2022-2025) and ending the HIV epidemic. In order to reach these goals, it is imperative for HIV care communities to address health care inequities. With the advent of FDA-approved long-acting injectable (LAI) antiretroviral (ARV) medication formulations, initiatives that promote, facilitate, and evaluate the uptake and ongoing utilization of LAI ARV medication may improve clinical outcomes for people with HIV, especially for minority populations who continue to face disparate health care inequities and stigma. This project is designed to develop protocols, implement them and modify as needed, to increase uptake of LAI ARV medications among people of color with HIV, since LAI ARV medications may offer benefits in addressing health inequities and achieving viral suppression. In addition to alleviating challenges associated with oral medications, ongoing utilization of LAI ARV medications in lieu of oral regimens may potentially reduce HIV-related stigma and enhance protection of health privacy. While there are some unique clinical and social benefits to this injectable drug formulation, some aspects of its distribution, administration requirements, and billing have already hindered uptake and utilization within the Ryan White HIV/AIDS Program (RWHAP). As minority populations have historically experienced significant disparities in accessing care and treatment, including the health literacy and access to health care coverage options necessary to engage in care, developing interventions to increase the uptake of LAI ARV medication formulations will help to proactively address and potentially reduce or prevent disparities minority communities may face in accessing this breakthrough therapy. The main objective of this program is to develop and implement protocols for successful use of LAI ARV medication within clinical practice. This program will fund 1 organization to serve as the Coordination and Evaluation Provider (CEP). The CEP must have the capacity and infrastructure (e.g., staffing/personnel, trainings, clinical systems, data collection and reporting, protocol and implementation evaluation) to support development, implementation, and refinement of LAI ARV medication administration protocols with the goal of replicating and expanding successful protocols. The recipient will solicit and subaward up to 10 demonstration sites (subrecipients) to implement these co-developed protocols and collect data from direct patient care, with priority given to entities located within EHE jurisdictions. HRSA anticipates that through evaluation and scale-up of LAI ARV medication administration protocols, patients with historic difficulty accessing or continuing oral HIV therapy can be bridged to this treatment modality, thus improving viral suppression and retention in care, especially among racial and ethnic minorities.
 
Collapse

 Application Information

Application Available 04/21/2022
Application Deadline 06/21/2022
Supplemental Application Deadline N/A
Explanation for Deadline N/A
Archive Date 08/20/2022
Letter of Intent Not required
Application Package SF424
Allow Applications to be Reopened in EHBs No
FOA Available Yes
Competitive Application Types Supported New
Allow Electronic Submission N/A
Page Limit for Application
Attachments
60
Allow Multiple Applications
from an Organization from Grants.gov
No
Electronic Submission Instruction Electronic submission is/will be available in Grants.Gov
 
Collapse

 General Information

Projected Award Date N/A
Estimated Project Period N/A
Estimated Project Start Date 09/01/2022
Estimated Project End Date 08/31/2026
Estimated Amount of this Competition $1,500,000.00
Estimated Number of Awards 1
Estimated Average Size of Awards $1,500,000.00
Cost Sharing No
Cooperative Agreement Yes
 
Collapse

 Contact Information

Name Susan Robilotto, D.O.
Email srobilotto@hrsa.gov
Phone Number (301)443-6554
 
Collapse

 Download Information

Expand FOA (Guidance) Attachment (Maximum 1)
Document Name Size Date Attached Description
HAB HRSA-22-155 (U1S) MHAF LAI_Final.pdf 397 kB 04/21/2022
Expand Application Package (Maximum 1)
No documents attached
Expand User Guide (Maximum 1)
No documents attached


Scroll to top